# Gerald Chan

> Gerald Chan is a Series A investor at Fudan University - School of Management backing Health Care. See 25 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Fudan University - School of Management](https://shizune.co/investors/profile/fudan-university-school-of-management)
- Total investments: 25
- Last investment: Mar 2026
- Lead investor: 96%
- Last updated: Aug 2026

Gerald Chan is a Series A investor at Fudan University - School of Management focused on Health Care and Health Diagnostics. Dr. Chan co-founded Morningside, a diversified investment group engaged primarily in private equity and venture capital investments in North America, Asia and Europe. Morningside commenced investing in China in 1992 and remains active in China’s internet, media and life sciences sectors.Dr. Chan is a director of publicly listed Hang Lung GroupLimited, a Hong Kong property holding company, and serves on the boards of several private biotechnology companies including CellCentric, Stealth Peptides, and Vaccine Technologies Inc.Dr. Chan is a trustee of Fudan University in Shanghai and sits on many advisory boards such as the International Society of Stem Cell Research Global Advisory Council, Cold Spring Harbor Conferences Asia, International Board of Governors of the New York Academy of Sciences and the Physical Sciences Visiting Committee of UCLA.Dr. Chan received his BS and MS degrees in Engineering from UCLA, and a Master of Science degree in Medical Radiological Physics and a Doctor of Science degree in Radiation Biology from Harvard University. He completed his post-doctoral training at the Dana Farber Cancer Institute.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Health Care | 7 | 28% |
| Health Diagnostics | 6 | 24% |
| Biotechnology | 4 | 16% |
| Artificial Intelligence | 4 | 16% |
| Medical | 3 | 12% |

32 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 6 | 24% |
| Series B | 3 | 12% |
| Funding Round | 3 | 12% |
| Seed | 1 | 4% |
| Series C | 1 | 4% |

6 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 12 | 48% |
| Canada | 2 | 8% |
| United Kingdom | 1 | 4% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Cognito Therapeutics | Cognito Therapeutics develops neurotechnology therapies designed to treat neurodegenerative diseases by stimulating specific brain activity patterns. The company focuses on noninvasive therapeutic systems that use synchronized visual and auditory stimulation to influence neural activity associated with cognitive function and brain health. Itstechnology platform, Spectris, is designed to evoke gamma-frequency brain waves, which play a role in learning, memory, and communication between neurons. The platform delivers controlled light and sound signals through a wearable device to trigger gamma oscillations in the brain, a pattern of neural activity that is disrupted in conditions such as Alzheimer’s disease. By restoring this activity, the therapy aims to support processes related to synaptic function, myelin integrity, and neural connectivity.Cognito Therapeutics conducts clinical research and trials to evaluate how its neuromodulation technology affects cognitive performance, brain structure, and functional abilities in patients with neurodegenerative disorders. The company studies the biological effects of sensory stimulation on brain pathways, immune responses, and neural signaling networks associated with disease progression. Through its research programs and device development, Cognito Therapeutics produces medical technologies intended for clinical treatment and investigation of neurological conditions that affect memory, cognition, and daily functioning. | $105M | Series C | Mar 05, 2026 |  |
| League | Founded in 2014, League is a technology-focused health company powering the digital transformation of healthcare. Employers, payers, pharmacy retailers and healthcare providers use our award-winning platform to deliver integrated and personalized health experiences that drive consumer engagement. Millions of people across the world use digitalhealth platforms powered by League to access, navigate and pay for care. |  | Venture - Series Unknown | Feb 28, 2025 |  |
| Casana | Casana is unlocking a new category in healthcare technologies that enable effortless, integrated and consistent in-home heart health monitoring. Casana’s first product, The Heart Seat™ is an IoT heart health toilet seat that captures clinically relevant measurements, including heart rate, blood pressure, blood oxygenation, and cardiac output.Casana’s mission is to assist medical teams in their care management of patients with chronic conditions beyond the four walls of the hospital, starting with the 6M+ people in the US living with Heart Failure. | $40M | Series B | Jan 21, 2022 |  |
| Casana | Casana is unlocking a new category in healthcare technologies that enable effortless, integrated and consistent in-home heart health monitoring. Casana’s first product, The Heart Seat™ is an IoT heart health toilet seat that captures clinically relevant measurements, including heart rate, blood pressure, blood oxygenation, and cardiac output.Casana’s mission is to assist medical teams in their care management of patients with chronic conditions beyond the four walls of the hospital, starting with the 6M+ people in the US living with Heart Failure. | $40M | Series B | Jan 21, 2022 |  |
| DeepCure | DeepCuris builds an AI engine for small-molecule drug discovery. | $40M | Series A | Nov 08, 2021 |  |
| DeepCure | DeepCuris builds an AI engine for small-molecule drug discovery. | $40M | Series A | Nov 08, 2021 |  |
| Linus Health | Linus Health is a Boston-based digital health company focused on transforming brain health for people across the world. By advancing how we detect and address cognitive and brain disorders – leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence – our goal is to enable a future where people can live longer, happier,and healthier lives with better brain health. Linus Health’s digital cognitive assessment platform delivers a proven, practical means of enabling early detection; empowers providers with actionable clinical insights; and supports individuals with personalized action plans. We are proud to partner with leading healthcare delivery organizations, research institutions, and life sciences companies to accelerate more proactive intervention and personalized care in brain health. | $55M | Series B | Jul 06, 2021 |  |
| Linus Health | Linus Health is a Boston-based digital health company focused on transforming brain health for people across the world. By advancing how we detect and address cognitive and brain disorders – leveraging cutting-edge neuroscience, clinical expertise, and artificial intelligence – our goal is to enable a future where people can live longer, happier,and healthier lives with better brain health. Linus Health’s digital cognitive assessment platform delivers a proven, practical means of enabling early detection; empowers providers with actionable clinical insights; and supports individuals with personalized action plans. We are proud to partner with leading healthcare delivery organizations, research institutions, and life sciences companies to accelerate more proactive intervention and personalized care in brain health. | $55M | Series B | Jul 06, 2021 |  |
| Stavvy | Stavvy is a modern lending experience designed to connect lenders with their title, settlement, and appraisal vendors. The Stavvy Connect is a fully-integrated, digital mortgage vendor platform that allows mortgage banking professionals to seamlessly and securely communicate and access vendor data & deliverables without fragmentation orexposure to unnecessary risk. The Stavvy Notarize empowers title agents, lawyers, notaries and other real estate professionals to leverage the power of web conference technology to conduct virtual closings and meetings in real-time. | $26.5M | Series A | Mar 24, 2021 |  |
| Stavvy | Stavvy is a modern lending experience designed to connect lenders with their title, settlement, and appraisal vendors. The Stavvy Connect is a fully-integrated, digital mortgage vendor platform that allows mortgage banking professionals to seamlessly and securely communicate and access vendor data & deliverables without fragmentation orexposure to unnecessary risk. The Stavvy Notarize empowers title agents, lawyers, notaries and other real estate professionals to leverage the power of web conference technology to conduct virtual closings and meetings in real-time. | $26.5M | Series A | Mar 24, 2021 |  |

10 of 25 investments shown.

## Co-investors
- [Morningside](https://shizune.co/investors/profile/morningside-technology-ventures) — VC Fund, 10 deals together
- [Morningside](https://shizune.co/investors/profile/morningside-group) — VC Fund, 5 deals together
- [5Y Capital](https://shizune.co/investors/profile/morningside-ventures) — VC Fund, 3 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 2 deals together
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund, 2 deals together
- [Arizona Tech Investors](https://shizune.co/investors/profile/arizona-technology-investor-forum) — VC Fund, 2 deals together

## About Fudan University - School of Management

VC Fund · Shanghai, China

Fudan University - School of Management is the first higher education institution founded by a Chinese person.

5 contacts available at Fudan University - School of Management.

| Name | Title | Profile |
| --- | --- | --- |
| Gerald Chan | Trustee | https://shizune.co/investors/profile/gerald-chan |
| Huisheng Peng | Professor of the Department of Macromolecular Science | https://shizune.co/investors/profile/huisheng-peng |
| Samantha DU | Adjunct Professor | https://shizune.co/investors/profile/dr-samantha-du |
| Tharon Smith | Director of Research - Venture Capital Investment | https://shizune.co/investors/profile/tharon-smith |
| Wu Xinbo | Executive Dean, Institute of International Studies | https://shizune.co/investors/profile/wu-xinbo |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Gerald Chan invest in?

Gerald Chan invests primarily in Health Care, Health Diagnostics and Biotechnology startups, most often at Series A and Series B stage. Most of the 25 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Gerald Chan last invest?

The most recent investment recorded for Gerald Chan closed in Mar 2026. Shizune tracks 25 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co